Nuvilex Inc. (NASDAQ:PMCB) Stock Short Interest Falls 47.6%

Nuvilex Inc. (NASDAQ:PMCB) saw a large decline in short interest in October. As of October 15th, there was short interest totaling 70,104 shares, a decline of 47.6% from the September 30th total of 133,885 shares. Based on an average daily trading volume, of 99,423 shares, the short-interest ratio is currently 0.7 days. Currently, 0.7% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 2nd. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Nuvilex has an average rating of “Sell”.

Nuvilex Stock Down 9.0%

Nuvilex stock traded down $0.03 during trading on Friday, reaching $0.30. The stock had a trading volume of 121,688 shares, compared to its average volume of 69,269. The business has a 50 day moving average price of $0.42 and a 200 day moving average price of $0.65. The stock has a market cap of $3.24 million, a PE ratio of -0.13 and a beta of 0.68. Nuvilex has a 52-week low of $0.30 and a 52-week high of $1.51.

Nuvilex (NASDAQ:PMCB) last released its quarterly earnings data on Monday, September 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.48).

About Nuvilex

Nuvilex, Inc was a biotechnology company that later changed its name to PharmaCyte Biotech, Inc and continued to trade under the ticker symbol PMCB. The company focused on developing cellular therapies intended to treat serious diseases, particularly cancer and diabetes.

Its primary technology involved encapsulating genetically engineered human cells in proprietary cellulose-based capsules. These cells were designed to produce therapeutic substances inside the body while limiting exposure to healthy tissue.